Modified Polypeptides for Fibrosis via PEGylation and Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrosis diseases are inadequate, with limited effective and safe drugs available, and existing therapies fail to effectively block or delay the progression of fibrotic lesions, leading to significant morbidity and mortality.
Innovation Solution
Development of chemically modified polypeptides that inhibit the TGF-β signaling pathway by amino acid deletion, substitution, or modification, combined with chemical modifications such as PEGylation, to enhance stability, solubility, and biological activity, thereby preventing and treating fibrosis diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptide drugs are used to treat fibrosis diseases, then high activity and low toxicity are achieved, but short half-life and low bioavailability occur due to enzymatic hydrolysis
Solution Approach 1:
The patent applies parameter changes by chemically modifying the polypeptide structure through PEGylation (adding polyethylene glycol chains) and amino acid substitutions. These modifications change the physical and chemical parameters of the polypeptide, including increasing molecular weight, altering hydrophilicity, and adding steric hindrance, which collectively protect against enzymatic degradation and extend half-life while maintaining therapeutic activity
Solution Approach 2:
The patent creates composite structures by combining the therapeutic polypeptide with PEG chains and other modifying groups. This composite approach allows the polypeptide to retain its biological activity while the PEG component provides protection against degradation and improves pharmacokinetic properties, effectively resolving the contradiction between activity and stability
2Stability of the object's composition
If chemical modification is applied to extend half-life, then stability is improved, but molecular structure and pharmacokinetics are altered
Solution Approach 1:
The patent systematically explores different modification parameters including PEG chain length, attachment positions, and amino acid substitution patterns. By optimizing these parameters, the patent achieves enhanced stability while maintaining favorable pharmacokinetic properties such as appropriate solubility, distribution, and clearance rates, thus balancing stability with pharmacokinetic adaptability
3Object-affected harmful factors
If polypeptide structure is simplified to reduce immunogenicity, then biocompatibility is improved, but biological activity may be reduced
Solution Approach 1:
The patent extracts and identifies the minimal essential sequence required for biological activity through systematic deletion studies. By removing non-essential amino acids and simplifying the structure to retain only the core active region, the patent reduces immunogenicity and molecular complexity while preserving the essential therapeutic function, effectively resolving the contradiction between simplicity and activity
Data Source
AI summary
Disclosed in the present invention are a polypeptide fragment, a derivative of the polypeptide fragment, and applications of the derivative of the polypeptide in the preparation of drugs for preventing and treating fibrosis diseases.